BridgeBio CFO granted 59,041 RSUs in equity award

Trimarchi Thomas reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Trimarchi Thomas reported acquisition or exercise transactions in this Form 4 filing.

BridgeBio Pharma, Inc. reported that its President and CFO, Thomas Trimarchi, received a grant of 59,041 restricted stock units (RSUs) of common stock as equity compensation. Each RSU represents a right to receive one share of common stock. The RSUs vest as to 1/16 of the underlying shares on May 16, 2026, and 1/16 each quarter thereafter, conditioned on his continued service. Following this grant, Trimarchi directly holds 395,626 shares of BridgeBio common stock.

Insider Trade Summary

Grant/Award: 59,041 shares

Grant/Award 1 txn

Insider Trimarchi Thomas

Role President and CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	59,041	$0.00	$0.00

Holdings After Transaction: Common Stock — 395,626 shares (Direct)

Footnotes (2)

1. F1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/16th of the underlying shares on May 16, 2026, and as to 1/16th of the underlying shares each quarter thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BridgeBio Pharma (BBIO) report for Thomas Trimarchi?

BridgeBio Pharma reported that President and CFO Thomas Trimarchi received a grant of 59,041 restricted stock units. These RSUs are equity compensation, not an open-market share purchase or sale, and increase his potential future ownership in BridgeBio common stock.

How many BridgeBio (BBIO) RSUs were granted to the President and CFO?

Thomas Trimarchi was granted 59,041 restricted stock units. Each RSU represents a contingent right to receive one share of BridgeBio common stock, subject to the vesting schedule and his continued service with the company or its subsidiaries through each vesting date.

What is the vesting schedule for Thomas Trimarchi’s BridgeBio (BBIO) RSU grant?

The RSU grant vests over time. One-sixteenth of the underlying shares vests on May 16, 2026, and one-sixteenth of the shares vests each quarter thereafter until fully vested, provided Trimarchi remains in service with BridgeBio or its subsidiaries.

Does the BridgeBio (BBIO) RSU grant to the CFO have an expiration date?

The RSUs granted to Thomas Trimarchi have no expiration date. They convert into BridgeBio common stock as they vest under the defined schedule, assuming he continues to provide service through each required vesting date as specified in the award terms.

How many BridgeBio (BBIO) shares does the CFO hold after this RSU grant?

After the RSU grant, Thomas Trimarchi is reported to beneficially own 395,626 shares of BridgeBio common stock directly. This figure reflects his holdings following the 59,041 RSU award disclosed in the insider transaction report filed for this grant.

Do the BridgeBio (BBIO) RSUs granted to the CFO represent immediate common shares?

The RSUs do not represent immediate common shares. Each restricted stock unit is a contingent right to receive one share of BridgeBio common stock, which is delivered only as the RSUs vest over time under the award’s service-based conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/20/2026 - 04:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trimarchi Thomas

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		A(1)		59,041	A	$0(2)	395,626	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs shall vest with respect to 1/16th of the underlying shares on May 16, 2026, and as to 1/16th of the underlying shares each quarter thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)